Lyell Immunopharma (NASDAQ:LYEL) Releases Earnings Results, Beats Expectations By $0.68 EPS

Lyell Immunopharma (NASDAQ:LYEL) announced its quarterly earnings data on Wednesday. The company reported ($2.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.81) by $0.68, FiscalAI reports. Lyell Immunopharma had a negative return on equity of 85.58% and a negative net margin of 552,328.31%.The business had revenue of $0.02 million for the quarter.

Lyell Immunopharma Stock Up 2.2%

Lyell Immunopharma stock traded up $0.38 during mid-day trading on Wednesday, hitting $17.63. The company had a trading volume of 12,957 shares, compared to its average volume of 72,090. Lyell Immunopharma has a 1 year low of $7.65 and a 1 year high of $23.40. The business has a fifty day moving average of $15.54 and a 200 day moving average of $11.84. The stock has a market cap of $338.67 million, a price-to-earnings ratio of -0.73 and a beta of -0.07.

Wall Street Analyst Weigh In

A number of research firms have issued reports on LYEL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Monday, September 1st. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $10.00.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of LYEL. AQR Capital Management LLC grew its position in shares of Lyell Immunopharma by 773.5% in the 1st quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock valued at $94,000 after buying an additional 154,327 shares during the last quarter. Acadian Asset Management LLC boosted its stake in Lyell Immunopharma by 204.2% in the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock valued at $354,000 after acquiring an additional 443,614 shares in the last quarter. Walleye Capital LLC purchased a new position in shares of Lyell Immunopharma during the second quarter worth about $258,000. Marshall Wace LLP acquired a new stake in shares of Lyell Immunopharma during the second quarter worth about $94,000. Finally, Orbimed Advisors LLC acquired a new stake in shares of Lyell Immunopharma during the second quarter worth about $457,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.